Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease

Clinical trial NCT00364858 · COMPLETED

Trial details

NCT number: NCT00364858
Sponsor: Genzyme, a Sanofi Company
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Gaucher Disease, Type 1 Cerebroside Lipidosis Syndrome Glucocerebrosidase Deficiency Disease Glucosylceramide Beta-Glucosidase Deficiency Disease Gaucher Disease, Non-Neuronopathic Form

Start date: 2001-12-01
Enrollment: 95

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.